Form 4: Nektar Therapeutics CEO Howard W. Robin Sells Shares to Cover Tax Obligations

Nektar Therapeutics CEO Howard W. Robin sold 23,774 shares of common stock on February 19, 2025, to cover tax withholding obligations related to vesting RSUs.

Summary

• On February 19, 2025, Howard W. Robin, the President and CEO of Nektar Therapeutics, sold 23,774 shares of Nektar Therapeutics common stock.
• The sale was executed to cover required tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs).
• The shares were sold at a weighted average price of $1.01, with individual transactions ranging from $1.00 to $1.04.
• Following the transaction, Robin directly owns 1,086,901 shares of Nektar Therapeutics common stock and indirectly owns 410 shares through a spouse.

Sentiment

Score: 5

Explanation: The document describes a routine transaction (selling shares to cover taxes on vested equity). It doesn't indicate positive or negative sentiment.

Industry Context

This is a routine Form 4 filing, which is common when company executives sell shares, especially to cover tax obligations related to equity compensation.

Stakeholder Impact

• The sale of shares by the CEO could have a minor negative impact on shareholder sentiment, although it is a common practice to cover tax obligations.

Key Dates

Keywords

Nektar Therapeutics, Howard W. Robin, stock sale, Form 4, tax withholding, RSUs, NKTR, insider trading